1
|
Synergistic pathogenicity by coinfection and sequential infection with JXA1-like HP-PRRSV and PCV2d in PCV2 antibody-positive post-weaned pigs. Microb Pathog 2022; 173:105810. [PMID: 36183959 DOI: 10.1016/j.micpath.2022.105810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Revised: 09/25/2022] [Accepted: 09/26/2022] [Indexed: 11/20/2022]
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) and Porcine circovirus (PCV) are two important pathogens, which caused respiratory disease in pigs. PRRSV and PCV2 had caused great economic losses to the pig industry. Pigs coinfection with PCV2 and PRRSV were common in the clinic, PCV2 antibodies can be detected in most of the pigs. PCV2d and HP-PRRSV(JXA1-like) were two major viruses circulating in the pigs in China. In this study, HP-PRRSV (JXA1-like) and PCV2d were used to coinfect and (or) sequential infect 5-week-old weaned PCV2-antibody positive pigs and the clinical indications, pathological, virus load, and specific antibodies of the challenged post-weaned piglets were evaluated. Thirty 5-week-old post-weaned pigs were divided into six groups infected with PBS, PCV2, PRRSV, PCV2-PRRSV, PRRSV-PCV2, and Co-PRRSV-PCV2 according to the PCV2 specific antibodies. Pigs infected with PRRSV can experience diarrhea, increased body temperature, weight loss, and even death. The pigs in PRRSV and PRRSV-PCV2 infected groups showed severe clinical symptoms, high mortality, and low average daily gain. The main pathological changes were widening of the lung interstitium, lung adhesion, and so on. The PRRSV-PCV2-infected group showed high levels of TNF-α and IL-2. In conclusion, PRRSV and PRRSV-PCV2 sequential infected pigs showed most pathogenic signs, and PCV2-PRRSV sequential infected pigs showed less pathogenicity than pigs of PCV2 and PRRSV coinfection and PRRSV monoinfection from day 10-14, partially suppressing the cytokine storm produced by PRRSV.
Collapse
|
2
|
Amiri M, Jafari S, Kurd M, Mohamadpour H, Khayati M, Ghobadinezhad F, Tavallaei O, Derakhshankhah H, Sadegh Malvajerd S, Izadi Z. Engineered Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as New Generations of Blood-Brain Barrier Transmitters. ACS Chem Neurosci 2021; 12:4475-4490. [PMID: 34841846 DOI: 10.1021/acschemneuro.1c00540] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The blood-brain barrier (BBB) is considered as the most challenging barrier in brain drug delivery. Indeed, there is a definite link between the BBB integrity defects and central nervous systems (CNS) disorders, such as neurodegenerative diseases and brain cancers, increasing concerns in the contemporary era because of the inability of most therapeutic approaches. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) have already been identified as having several advantages in facilitating the transportation of hydrophilic and hydrophobic agents across the BBB. This review first explains BBB functions and its challenges in brain drug delivery, followed by a brief description of nanoparticle-based drug delivery for brain diseases. A detailed presentation of recent progressions in optimizing SLNs and NLCs for controlled release drug delivery, gene therapy, targeted drug delivery, and diagnosis of neurodegenerative diseases and brain cancers is approached. Finally, the problems, challenges, and future perspectives in optimizing these carriers for potential clinical application were described briefly.
Collapse
Affiliation(s)
- Mahtab Amiri
- Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
- USERN Office, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
| | - Samira Jafari
- Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
- USERN Office, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
| | - Masoumeh Kurd
- Trita Nanomedicine Research Center (TNRC), Trita Third Millennium Pharmaceuticals, Tehran 15469-13111, Iran
| | - Hamed Mohamadpour
- Department of Pharmaceutical Nanotechnology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan 45139-56184, Iran
| | - Maryam Khayati
- Department of Pharmaceutical Nanotechnology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan 45139-56184, Iran
| | - Farbod Ghobadinezhad
- USERN Office, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
- Student’s Research Committee, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
| | - Omid Tavallaei
- Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
- USERN Office, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
| | - Hossein Derakhshankhah
- Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
- USERN Office, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
| | - Soroor Sadegh Malvajerd
- USERN Office, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
- Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran
| | - Zhila Izadi
- Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
- USERN Office, Kermanshah University of Medical Sciences, Kermanshah 6715847141, Iran
| |
Collapse
|
3
|
Mitxelena-Iribarren O, Lizarbe-Sancha S, Campisi J, Arana S, Mujika M. Different Microfluidic Environments for In Vitro Testing of Lipid Nanoparticles against Osteosarcoma. Bioengineering (Basel) 2021; 8:bioengineering8060077. [PMID: 34199965 PMCID: PMC8228877 DOI: 10.3390/bioengineering8060077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 05/27/2021] [Accepted: 06/03/2021] [Indexed: 11/18/2022] Open
Abstract
The use of lipid nanoparticles as biodegradable shells for controlled drug delivery shows promise as a more effective and targeted tumor treatment than traditional treatment methods. Although the combination of target therapy with nanotechnology created new hope for cancer treatment, methodological issues during in vitro validation of nanovehicles slowed their application. In the current work, the effect of methotrexate (MTX) encapsulated in different matrices was evaluated in a dynamic microfluidic platform. Effects on the viability of osteosarcoma cells in the presence of recirculation of cell media, free MTX and two types of blank and drug-containing nanoparticles were successfully assessed in different tumor-mimicking microenvironments. Encapsulated MTX was more effective than the equal dose free drug treatment, as cell death significantly increased under the recirculation of both types of drug-loaded nanoparticles in all concentrations. In fact, MTX-nanoparticles reduced cell population 50 times more than the free drug when 150-µM drug dose was recirculated. Moreover, when compared to the equivalent free drug dose recirculation, cell number was reduced 60 and 100 points more under recirculation of each nanoparticle with a 15-µM drug concentration. Thus, the results obtained with the microfluidic model present MTX-lipid nanoparticles as a promising and more effective therapy for pediatric osteosarcoma treatment than current treatment options.
Collapse
Affiliation(s)
- Oihane Mitxelena-Iribarren
- CEIT-Basque Research and Technology Alliance (BRTA), Manuel Lardizábal 15, 20018 Donostia-San Sebastián, Spain; (S.L.-S.); (J.C.); (S.A.); (M.M.)
- School of Engineering at San Sebastián, Universidad de Navarra, Manuel Lardizábal 13, 20018 Donostia-San Sebastián, Spain
- Correspondence:
| | - Sara Lizarbe-Sancha
- CEIT-Basque Research and Technology Alliance (BRTA), Manuel Lardizábal 15, 20018 Donostia-San Sebastián, Spain; (S.L.-S.); (J.C.); (S.A.); (M.M.)
- School of Engineering at San Sebastián, Universidad de Navarra, Manuel Lardizábal 13, 20018 Donostia-San Sebastián, Spain
| | - Jay Campisi
- CEIT-Basque Research and Technology Alliance (BRTA), Manuel Lardizábal 15, 20018 Donostia-San Sebastián, Spain; (S.L.-S.); (J.C.); (S.A.); (M.M.)
- School of Engineering at San Sebastián, Universidad de Navarra, Manuel Lardizábal 13, 20018 Donostia-San Sebastián, Spain
- Department of Biology, Regis University, Denver, CO 80221, USA
| | - Sergio Arana
- CEIT-Basque Research and Technology Alliance (BRTA), Manuel Lardizábal 15, 20018 Donostia-San Sebastián, Spain; (S.L.-S.); (J.C.); (S.A.); (M.M.)
- School of Engineering at San Sebastián, Universidad de Navarra, Manuel Lardizábal 13, 20018 Donostia-San Sebastián, Spain
| | - Maite Mujika
- CEIT-Basque Research and Technology Alliance (BRTA), Manuel Lardizábal 15, 20018 Donostia-San Sebastián, Spain; (S.L.-S.); (J.C.); (S.A.); (M.M.)
- School of Engineering at San Sebastián, Universidad de Navarra, Manuel Lardizábal 13, 20018 Donostia-San Sebastián, Spain
| |
Collapse
|
4
|
Li S, Yang Y, Lin X, Li Z, Ma G, Su Z, Zhang S. Biocompatible cationic solid lipid nanoparticles as adjuvants effectively improve humoral and T cell immune response of foot and mouth disease vaccines. Vaccine 2020; 38:2478-2486. [PMID: 32057580 DOI: 10.1016/j.vaccine.2020.02.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2019] [Revised: 01/17/2020] [Accepted: 02/02/2020] [Indexed: 12/12/2022]
Abstract
In this work, we explored the potential of cationic solid lipid nanoparticles (cSLN) as efficient adjuvants for inactivated foot and mouth disease virus (iFMDV) vaccine. The cSLN were prepared by O/W emulsion method with Compritol 888 ATO as lipid matrix, and were modified by cationic lipid Didodecyldimethylammonium bromide (DDAB). The content of cationic lipid was optimized to produce cSLN with appropriate particle size, surface morphology, zeta potential, and polydispersity. Loading iFMDV onto cSLN by electrostatic attraction did not destruct iFMDV particle structure as measured by high performance size exclusion chromatography (HPSEC). Differential scanning fluorimetry (DSF) showed the transition temperature, Tm, related to iFMDV dissociation increased for 1.2 °C after loading on cSLN, indicating an enhanced stability of this unstable antigen. The cSLN loaded iFMDV enhanced in vitro antigen uptake and activation of bone-marrow-derived dendritic cells (BMDCs) with augmented expression of CD86, CD40, and MHC I. In animal trials, BALB/c mice were immunized with free iFMDV, antigen adjuvanted with the cSLN, and antigen adjuvanted with Montanide ISA 206 emulsion. Specific antibody titers showed cSLN could stimulate similar FMDV-specific IgG and IgG subclasses antibody level compared with the widely used ISA 206. In addition, cSLN significantly enhanced memory immune response including effector-memory T cells and central-memory T cells compared to free iFMDV antigen and antigen adjuvanted with ISA 206. Taken together the enhanced humoral and T cell immune responses and the antigen structure friendly properties, cSLN can be a potential adjuvant for iFMDV vaccines.
Collapse
Affiliation(s)
- Shuai Li
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China; University of Chinese Academy of Sciences, Beijing 100049, PR China
| | - Yanli Yang
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
| | - Xuan Lin
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China; University of Chinese Academy of Sciences, Beijing 100049, PR China
| | - Zhengjun Li
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
| | - Guanghui Ma
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
| | - Zhiguo Su
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China.
| | - Songping Zhang
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China.
| |
Collapse
|
5
|
Wang CY, Fang YX, Chen GH, Jia HJ, Zeng S, He XB, Feng Y, Li SJ, Jin QW, Cheng WY, Jing ZZ. Analysis of the CDR3 length repertoire and the diversity of T cell receptor α and β chains in swine CD4+ and CD8+ T lymphocytes. Mol Med Rep 2017; 16:75-86. [PMID: 28534993 PMCID: PMC5482108 DOI: 10.3892/mmr.2017.6601] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2016] [Accepted: 02/20/2017] [Indexed: 11/13/2022] Open
Abstract
The T cell receptor (TCR) is a complex heterodimer that recognizes fragments of antigens as peptides and binds to major histocompatibility complex molecules. The TCR α and β chains possess three hypervariable regions termed complementarity determining regions (CDR1, 2 and 3). CDR3 is responsible for recognizing processed antigen peptides. Immunoscope spectratyping is a simple technique for analyzing CDR3 polymorphisms and sequence length diversity, in order to investigate T cell function and the pattern of TCR utilization. The present study employed this technique to analyze CDR3 polymorphisms and the sequence length diversity of TCR α and β chains in porcine CD4+ and CD8+ T cells. Polymerase chain reaction products of 19 TCR α variable regions (AV) and 20 TCR β variable regions (BV) gene families obtained from the CD4+ and CD8+ T cells revealed a clear band following separation by 1.5% agarose gel electrophoresis, and each family exhibited >8 bands following separation by 6% sequencing gel electrophoresis. CDR3 spectratyping of all identified TCR AV and BV gene families in the sorted CD4+ and CD8+ T cells by GeneScan, demonstrated a standard Gaussian distribution with >8 peaks. CDR3 in CD4+ and CD8+ T cells demonstrated different expression patterns. The majority of CDR3 recombined in frame and the results revealed that there were 10 and 14 amino acid discrepancies between the longest and shortest CDR3 lengths in specific TCR AV and TCR BV gene families, respectively. The results demonstrated that CDR3 polymorphism and length diversity demonstrated different expression and utilization patterns in CD4+ and CD8+ T cells. These results may facilitate future research investigating the porcine TCR CDR3 gene repertoire as well as the functional complexity and specificity of the TCR molecule.
Collapse
Affiliation(s)
- Chun-Yan Wang
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, P.R. China
| | - Yong-Xiang Fang
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, P.R. China
| | - Guo-Hua Chen
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, P.R. China
| | - Huai-Jie Jia
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, P.R. China
| | - Shuang Zeng
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, P.R. China
| | - Xiao-Bing He
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, P.R. China
| | - Yuan Feng
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, P.R. China
| | - Shou-Jie Li
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, P.R. China
| | - Qi-Wang Jin
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, P.R. China
| | - Wen-Yu Cheng
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, P.R. China
| | - Zhi-Zhong Jing
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Public Health of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, P.R. China
| |
Collapse
|
6
|
Robinson L, Knight-Jones TJD, Charleston B, Rodriguez LL, Gay CG, Sumption KJ, Vosloo W. Global Foot-and-Mouth Disease Research Update and Gap Analysis: 3 - Vaccines. Transbound Emerg Dis 2017; 63 Suppl 1:30-41. [PMID: 27320164 DOI: 10.1111/tbed.12521] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2016] [Indexed: 11/28/2022]
Abstract
This study assessed research knowledge gaps in the field of FMDV (foot-and-mouth disease virus) vaccines. The study took the form of a literature review (2011-15) combined with research updates collected in 2014 from 33 institutes from across the world. Findings were used to identify priority areas for future FMD vaccine research. Vaccines play a vital role in FMD control, used both to limit the spread of the virus during epidemics in FMD-free countries and as the mainstay of disease management in endemic regions, particularly where sanitary controls are difficult to apply. Improvements in the performance or cost-effectiveness of FMD vaccines will allow more widespread and efficient disease control. FMD vaccines have changed little in recent decades, typically produced by inactivation of whole virus, the quantity and stability of the intact viral capsids in the final preparation being key for immunogenicity. However, these are exciting times and several promising novel FMD vaccine candidates have recently been developed. This includes the first FMD vaccine licensed for manufacture and use in the USA; this adenovirus-vectored FMD vaccine causes in vivo expression of viral capsids in vaccinated animals. Another promising vaccine candidate comprises stabilized empty FMDV capsids produced in vitro in a baculovirus expression system. Recombinant technologies are also being developed to improve otherwise conventionally produced inactivated vaccines, for example, by creating a chimeric vaccine virus to increase capsid stability and by inserting sequences into the vaccine virus for desired antigen expression. Other important areas of ongoing research include enhanced adjuvants, vaccine quality control procedures and predicting vaccine protection from immune correlates, thus reducing dependency on animal challenge studies. Globally, the degree of independent vaccine evaluation is highly variable, and this is essential for vaccine quality. Previously neglected, the importance of evaluating vaccination programme effectiveness and impact is increasingly being recognized.
Collapse
Affiliation(s)
| | | | | | - L L Rodriguez
- Plum Island Animal Disease Center, ARS, USDA, Greenport, NY, USA
| | - C G Gay
- Agricultural Research Service, USDA, National Program 103-Animal Health, Beltsville, MD, USA
| | - K J Sumption
- European Commission for the Control of FMD (EuFMD), FAO, Rome, Italy
| | - W Vosloo
- Australian Animal Health Laboratory, CSIRO-Biosecurity Flagship, Geelong, Vic., Australia
| |
Collapse
|
7
|
Jain S, Patel N, Shah MK, Khatri P, Vora N. Recent Advances in Lipid-Based Vesicles and Particulate Carriers for Topical and Transdermal Application. J Pharm Sci 2016; 106:423-445. [PMID: 27865609 DOI: 10.1016/j.xphs.2016.10.001] [Citation(s) in RCA: 115] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 10/02/2016] [Accepted: 10/03/2016] [Indexed: 12/12/2022]
Abstract
In the recent decade, skin delivery (topical and transdermal) has gained an unprecedented popularity, especially due to increased incidences of chronic skin diseases, demand for targeted and patient compliant delivery, and interest in life cycle management strategies among pharmaceutical companies. Literature review of recent publications indicates that among various skin delivery systems, lipid-based delivery systems (vesicular carriers and lipid particulate systems) have been the most successful. Vesicular carriers consist of liposomes, ultradeformable liposomes, and ethosomes, while lipid particulate systems consist of lipospheres, solid lipid nanoparticles, and nanostructured lipid carriers. These systems can increase the skin drug transport by improving drug solubilization in the formulation, drug partitioning into the skin, and fluidizing skin lipids. Considering that lipid-based delivery systems are regarded as safe and efficient, they are proving to be an attractive delivery strategy for the pharmaceutical as well as cosmeceutical drug substances. However, development of these delivery systems requires comprehensive understanding of physicochemical characteristics of drug and delivery carriers, formulation and process variables, mechanism of skin delivery, recent technological advancements, specific limitations, and regulatory considerations. Therefore, this review article encompasses recent research advances addressing the aforementioned issues.
Collapse
Affiliation(s)
- Shashank Jain
- Department of Product Development, G & W Labs, 101 Coolidge Street, South Plainfield, New Jersey 07080.
| | - Niketkumar Patel
- Charles River Laboratories Contract Manufacturing PA, LLC, Boothwyn, Pennsylvania 19061
| | - Mansi K Shah
- Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas 77555
| | - Pinak Khatri
- Department of Product Development, G & W PA Laboratories, Sellersville, Pennsylvania 18960
| | - Namrata Vora
- Department of Formulation Development, Capsugel Dosage Form Solutions Division, Xcelience, Tampa, Florida 33634
| |
Collapse
|
8
|
Overview on experimental models of interactions between nanoparticles and the immune system. Biomed Pharmacother 2016; 83:1365-1378. [DOI: 10.1016/j.biopha.2016.08.060] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Revised: 08/14/2016] [Accepted: 08/24/2016] [Indexed: 01/05/2023] Open
|
9
|
Geszke-Moritz M, Moritz M. Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2016; 68:982-994. [PMID: 27524099 DOI: 10.1016/j.msec.2016.05.119] [Citation(s) in RCA: 197] [Impact Index Per Article: 24.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/13/2015] [Revised: 04/24/2016] [Accepted: 05/27/2016] [Indexed: 12/22/2022]
Abstract
This work briefly reviews up-to-date developments in solid lipid nanoparticles (SLNs) as effective nanocolloidal system for drug delivery. It summarizes SLNs in terms of their preparation, surface modification and properties. The application of SLNs as a carrier system enables to improve the therapeutic efficacy of drugs from various therapeutic groups. Present uses of SLNs include cancer therapy, dermatology, bacterial infections, brain targeting and eye disorders among others. The usage of SLNs provides enhanced pharmacokinetic properties and modulated release of drugs. SLN ubiquitous application results from their specific features such as possibility of surface modification, increased permeation through biological barriers, resistance to chemical degradation, possibility of co-delivery of various therapeutic agents or stimuli-responsiveness. This paper will be useful to the scientists working in the domain of SLN-based drug delivery systems.
Collapse
Affiliation(s)
| | - Michał Moritz
- Poznan University of Technology, Faculty of Chemical Technology, Institute of Chemistry and Technical Electrochemistry, Berdychowo 4, 60-965 Poznań, Poland.
| |
Collapse
|